Skip to main content

About Revonto
Revonto is indicated, with appropriate supportive measures, for the treatment of malignant hyperthermia
About Revonto

How to Use

check icon
Revonto (dantrolene sodium for injection) is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages.
check icon
Revonto is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
20 Seconds

Revonto has a shelf life of 36 months* and
is ready to administer in 2o seconds

*from the date of manufacture
† or until solution is clear


How to administer

Revonto should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever).

Important note: The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously known supportive measures. These measures must be individualized, but it will usually be necessary to discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for electrolyte imbalance.
Revonto vial
Cost Savings

US WorldMeds introduced Revonto at the same
cost-savings as its original generic product.

Please see full prescribing information for Revonto.

Open ISI